BELLUS Health Inc. (BLU) |
| 14.745 0.005 (0.03%) 06-28 15:59 |
| Open: | 14.74 |
| High: | 14.75 |
| Low: | 14.74 |
| Volume: | 2,839,350 |
| Market Cap: | 1,870(M) |
| PE Ratio: | -20.2 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 72.52 |
| Resistance 1: | 62.09 |
| Pivot price: | 59.54 |
| Support 1: | 59.53 |
| Support 2: | 57.95 |
| 52w High: | 14.76 |
| 52w Low: | 6.38 |
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 31 Jul 2026
BELLUS Health Inc. Revenue Breakdown – BMV:BLU/N - TradingView
Fri, 16 Jun 2023
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders - Business Wire
Fri, 12 May 2023
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Business Wire
Tue, 18 Apr 2023
GSK bets $2 bln on Bellus cough drug to soothe pipeline fears - Reuters
Tue, 18 Apr 2023
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health - GSK US
Tue, 21 Mar 2023
BELLUS Health Reports Year 2022 Financial Results and Business Highlights - Business Wire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
